Trial Profile

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-active Secondary Progressive Multiple Sclerosis

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 02 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Orelabrutinib (Primary)
Indications Multiple sclerosis
Focus Registrational; Therapeutic Use
Sponsors Zenas BioPharma

Most Recent Events

27 Mar 2026 According to Zenas BioPharma media release, the company will use the net proceeds from the Convertible Notes Offering and the Equity Offering for funding the ongoing and planned orelabrutinib Phase 3 clinical trials for progressive multiple sclerosis.
20 Mar 2026 Status changed from not yet recruiting to recruiting.
12 Jan 2026 Planned number of patients changed from 330 to 990.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com